Accelerate the development of broad and ultra-potent anti-HIV-1 antibodies through licensing or direct investment.
These novel anti-HIV-1 antibodies are broader and more potent than a majority of anti-HIV-1 human broadly neutralising antibodies and present an opportunity for a platform technology for rapid discovery and testing of therapeutic antibodies.
The innovation
Using ten novel anti-HIV-1 antibodies, immunotherapy has the potential to suppress infection and increase the rate of clearance of infected cells.
Market need
There are no means to cure or prevent HIV infection. Approximately 38.4 million people were living with HIV at the end of 2021, with an estimated 1.5 million people per year becoming newly infected globally. Anti-retroviral therapy is a lifelong treatment which requires diligent adherence and can be associated with toxicity and significant economic costs.
Innovation status
The novel anti-HIV-1 antibodies demonstrate superior breadth and potency in comparison to clinical stage antibodies. Further preclinical evaluation is currently underway. There is also an opportunity for a platform technology for rapid discovery and testing of therapeutic antibodies.
Contact
Dr Anna Malinovitch
anna.malinovitch@unimelb.edu.au
Flyer
Download flyer for more information (PDF, 630 KB)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.